At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
SL-801drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating SL-801 for Solid Tumors. Completed, enrolled 72 participants across 6 sites.
Detailed Summary
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionOct 2021
Study CompletionOct 2021
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartFeb 23, 2016
Primary CompletionOct 6, 2021
Study CompletionOct 13, 2021
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 10.4 years ago
Interventions
SL-801drug
SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).